JP5198290B2 - 免疫反応を誘発する酵母ベースワクチン - Google Patents
免疫反応を誘発する酵母ベースワクチン Download PDFInfo
- Publication number
- JP5198290B2 JP5198290B2 JP2008553534A JP2008553534A JP5198290B2 JP 5198290 B2 JP5198290 B2 JP 5198290B2 JP 2008553534 A JP2008553534 A JP 2008553534A JP 2008553534 A JP2008553534 A JP 2008553534A JP 5198290 B2 JP5198290 B2 JP 5198290B2
- Authority
- JP
- Japan
- Prior art keywords
- yeast
- protein
- antigen
- influenza
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 629
- 230000028993 immune response Effects 0.000 title claims description 112
- 229960005486 vaccine Drugs 0.000 title description 313
- 239000000427 antigen Substances 0.000 claims abstract description 747
- 108091007433 antigens Proteins 0.000 claims abstract description 745
- 102000036639 antigens Human genes 0.000 claims abstract description 745
- 239000000203 mixture Substances 0.000 claims abstract description 113
- 230000003834 intracellular effect Effects 0.000 claims abstract description 64
- 108090000623 proteins and genes Proteins 0.000 claims description 234
- 102000004169 proteins and genes Human genes 0.000 claims description 217
- 206010022000 influenza Diseases 0.000 claims description 180
- 210000004027 cell Anatomy 0.000 claims description 120
- 230000014509 gene expression Effects 0.000 claims description 98
- 108020001507 fusion proteins Proteins 0.000 claims description 95
- 102000037865 fusion proteins Human genes 0.000 claims description 95
- 241000712461 unidentified influenza virus Species 0.000 claims description 80
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 67
- 241001465754 Metazoa Species 0.000 claims description 58
- 210000005253 yeast cell Anatomy 0.000 claims description 51
- 239000012528 membrane Substances 0.000 claims description 48
- 238000002360 preparation method Methods 0.000 claims description 31
- 230000036039 immunity Effects 0.000 claims description 30
- 108010059722 Viral Fusion Proteins Proteins 0.000 claims description 28
- 108010006232 Neuraminidase Proteins 0.000 claims description 27
- 102000005348 Neuraminidase Human genes 0.000 claims description 27
- 230000003053 immunization Effects 0.000 claims description 22
- 230000002163 immunogen Effects 0.000 claims description 22
- 230000001939 inductive effect Effects 0.000 claims description 21
- 101710154606 Hemagglutinin Proteins 0.000 claims description 20
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 20
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 20
- 101710176177 Protein A56 Proteins 0.000 claims description 20
- 239000000185 hemagglutinin Substances 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 241000235648 Pichia Species 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 10
- 241000235070 Saccharomyces Species 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 210000000805 cytoplasm Anatomy 0.000 claims description 7
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 6
- 241000235346 Schizosaccharomyces Species 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 101710186708 Agglutinin Proteins 0.000 claims description 3
- 101710146024 Horcolin Proteins 0.000 claims description 3
- 101710189395 Lectin Proteins 0.000 claims description 3
- 101710179758 Mannose-specific lectin Proteins 0.000 claims description 3
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 claims description 3
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 claims description 3
- 239000000910 agglutinin Substances 0.000 claims description 3
- 210000000601 blood cell Anatomy 0.000 claims description 3
- 101800001707 Spacer peptide Proteins 0.000 claims 3
- 101800001415 Bri23 peptide Proteins 0.000 claims 1
- 101800000655 C-terminal peptide Proteins 0.000 claims 1
- 102400000107 C-terminal peptide Human genes 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 235000021419 vinegar Nutrition 0.000 claims 1
- 239000000052 vinegar Substances 0.000 claims 1
- 244000052769 pathogen Species 0.000 abstract description 125
- 238000000034 method Methods 0.000 abstract description 121
- 230000001717 pathogenic effect Effects 0.000 abstract description 92
- 201000010099 disease Diseases 0.000 abstract description 66
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 66
- 208000015181 infectious disease Diseases 0.000 abstract description 53
- 230000028996 humoral immune response Effects 0.000 abstract description 39
- 230000001225 therapeutic effect Effects 0.000 abstract description 16
- 230000002458 infectious effect Effects 0.000 abstract description 4
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 607
- 239000003981 vehicle Substances 0.000 description 233
- 150000007523 nucleic acids Chemical class 0.000 description 77
- 241000700605 Viruses Species 0.000 description 64
- 102000039446 nucleic acids Human genes 0.000 description 62
- 108020004707 nucleic acids Proteins 0.000 description 62
- 150000001413 amino acids Chemical class 0.000 description 55
- 239000000969 carrier Substances 0.000 description 52
- 125000003275 alpha amino acid group Chemical group 0.000 description 43
- 230000024932 T cell mediated immunity Effects 0.000 description 35
- 210000004443 dendritic cell Anatomy 0.000 description 34
- 239000002245 particle Substances 0.000 description 25
- 210000002421 cell wall Anatomy 0.000 description 22
- 230000004927 fusion Effects 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 21
- 108010058643 Fungal Proteins Proteins 0.000 description 20
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 20
- 238000013459 approach Methods 0.000 description 20
- 210000003719 b-lymphocyte Anatomy 0.000 description 19
- 230000001413 cellular effect Effects 0.000 description 19
- 229960003971 influenza vaccine Drugs 0.000 description 18
- 125000006850 spacer group Chemical group 0.000 description 18
- 108010041986 DNA Vaccines Proteins 0.000 description 17
- 229940021995 DNA vaccine Drugs 0.000 description 17
- 239000002671 adjuvant Substances 0.000 description 17
- 230000003612 virological effect Effects 0.000 description 17
- 230000007969 cellular immunity Effects 0.000 description 16
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 16
- 230000006698 induction Effects 0.000 description 16
- 238000002649 immunization Methods 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 238000002255 vaccination Methods 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 230000027455 binding Effects 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 210000000987 immune system Anatomy 0.000 description 14
- 239000003607 modifier Substances 0.000 description 14
- 230000004727 humoral immunity Effects 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 229940031626 subunit vaccine Drugs 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- 108090000862 Ion Channels Proteins 0.000 description 11
- 102000004310 Ion Channels Human genes 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 238000009169 immunotherapy Methods 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 241000725303 Human immunodeficiency virus Species 0.000 description 10
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 229930182817 methionine Natural products 0.000 description 10
- 230000007935 neutral effect Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 108010001267 Protein Subunits Proteins 0.000 description 9
- 102000002067 Protein Subunits Human genes 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 230000004481 post-translational protein modification Effects 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 108060003393 Granulin Proteins 0.000 description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000002443 helper t lymphocyte Anatomy 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000004475 Arginine Substances 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
- 230000008512 biological response Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000016784 immunoglobulin production Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000037452 priming Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 102000018697 Membrane Proteins Human genes 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 6
- 206010057249 Phagocytosis Diseases 0.000 description 6
- 108010067390 Viral Proteins Proteins 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 239000012678 infectious agent Substances 0.000 description 6
- 230000008782 phagocytosis Effects 0.000 description 6
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 5
- 108010065805 Interleukin-12 Proteins 0.000 description 5
- 102000013462 Interleukin-12 Human genes 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 229940028617 conventional vaccine Drugs 0.000 description 5
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 235000021472 generally recognized as safe Nutrition 0.000 description 5
- 230000036252 glycation Effects 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 229940117681 interleukin-12 Drugs 0.000 description 5
- 230000004807 localization Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000000527 sonication Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 4
- 102000019265 Cytochrome c1 Human genes 0.000 description 4
- 108010007528 Cytochromes c1 Proteins 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 244000285963 Kluyveromyces fragilis Species 0.000 description 4
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 4
- 241000204031 Mycoplasma Species 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 4
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000036755 cellular response Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 239000000367 immunologic factor Substances 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 229960003130 interferon gamma Drugs 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 3
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 3
- 241000588832 Bordetella pertussis Species 0.000 description 3
- 101150038242 GAL10 gene Proteins 0.000 description 3
- 102000048120 Galactokinases Human genes 0.000 description 3
- 108700023157 Galactokinases Proteins 0.000 description 3
- 102100024637 Galectin-10 Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 241000713196 Influenza B virus Species 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 3
- 102000006321 UTP-hexose-1-phosphate uridylyltransferase Human genes 0.000 description 3
- 108010058532 UTP-hexose-1-phosphate uridylyltransferase Proteins 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000009056 active transport Effects 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- -1 complex Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000007813 immunodeficiency Effects 0.000 description 3
- 230000001024 immunotherapeutic effect Effects 0.000 description 3
- 208000037797 influenza A Diseases 0.000 description 3
- 108700010900 influenza virus proteins Proteins 0.000 description 3
- 229940076144 interleukin-10 Drugs 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000005195 poor health Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 210000001938 protoplast Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940021747 therapeutic vaccine Drugs 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 101150022075 ADR1 gene Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 230000003844 B-cell-activation Effects 0.000 description 2
- 241000714266 Bovine leukemia virus Species 0.000 description 2
- 101100480861 Caldanaerobacter subterraneus subsp. tengcongensis (strain DSM 15242 / JCM 11007 / NBRC 100824 / MB4) tdh gene Proteins 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 101100447466 Candida albicans (strain WO-1) TDH1 gene Proteins 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 241000714165 Feline leukemia virus Species 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 229940033330 HIV vaccine Drugs 0.000 description 2
- 101000734572 Homo sapiens Phosphoenolpyruvate carboxykinase, cytosolic [GTP] Proteins 0.000 description 2
- 241001500351 Influenzavirus A Species 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 241000320412 Ogataea angusta Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102100034796 Phosphoenolpyruvate carboxykinase, cytosolic [GTP] Human genes 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 241000223810 Plasmodium vivax Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 101150014136 SUC2 gene Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical group C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 210000005220 cytoplasmic tail Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 108010017271 denileukin diftitox Proteins 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000001589 lymphoproliferative effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229960005030 other vaccine in atc Drugs 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000013823 prenylation Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 229940023143 protein vaccine Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 108010038379 sargramostim Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000003046 sporozoite Anatomy 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 101150088047 tdh3 gene Proteins 0.000 description 2
- 230000003614 tolerogenic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 229940118696 vibrio cholerae Drugs 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100029464 Aquaporin-9 Human genes 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000244036 Brugia Species 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101150004278 CYC1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101100120289 Drosophila melanogaster Flo1 gene Proteins 0.000 description 1
- 102100026620 E3 ubiquitin ligase TRAF3IP2 Human genes 0.000 description 1
- 101710140859 E3 ubiquitin ligase TRAF3IP2 Proteins 0.000 description 1
- 102100023431 E3 ubiquitin-protein ligase TRIM21 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 108090000698 Formate Dehydrogenases Proteins 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 238000012424 Freeze-thaw process Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150077230 GAL4 gene Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- FYYSIASRLDJUNP-WHFBIAKZSA-N Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FYYSIASRLDJUNP-WHFBIAKZSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 244000286779 Hansenula anomala Species 0.000 description 1
- 235000014683 Hansenula anomala Nutrition 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108700008783 Hepatitis C virus E1 Proteins 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 101000771413 Homo sapiens Aquaporin-9 Proteins 0.000 description 1
- 101000685877 Homo sapiens E3 ubiquitin-protein ligase TRIM21 Proteins 0.000 description 1
- 101000921370 Homo sapiens Elongation of very long chain fatty acids protein 1 Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000192017 Micrococcaceae Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000222051 Papiliotrema laurentii Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241000606752 Pasteurellaceae Species 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 241000223254 Rhodotorula mucilaginosa Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000606683 Rickettsiaceae Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 101100451671 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SSA3 gene Proteins 0.000 description 1
- 101100451681 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SSA4 gene Proteins 0.000 description 1
- 235000018368 Saccharomyces fragilis Nutrition 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 101150033985 TPI gene Proteins 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 108010075202 UDP-glucose 4-epimerase Proteins 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607493 Vibrionaceae Species 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 229940060265 aldara Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical class [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical class O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012178 germinal center formation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000006057 immunotolerant effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 229940031154 kluyveromyces marxianus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960001226 live attenuated influenza Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 210000003936 merozoite Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 102000027507 nuclear receptors type II Human genes 0.000 description 1
- 108091008686 nuclear receptors type II Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940100027 ontak Drugs 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000000680 phagosome Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000013858 positive regulation of humoral immune response Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940076376 protein agonist Drugs 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000017960 syncytium formation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 229940023147 viral vector vaccine Drugs 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16311—Influenzavirus C, i.e. influenza C virus
- C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76502506P | 2006-02-02 | 2006-02-02 | |
| US60/765,025 | 2006-02-02 | ||
| PCT/US2007/061572 WO2007092792A2 (en) | 2006-02-02 | 2007-02-02 | Yeast-based vaccine for inducing an immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012260860A Division JP2013075899A (ja) | 2006-02-02 | 2012-11-29 | 治療用組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009528987A JP2009528987A (ja) | 2009-08-13 |
| JP2009528987A5 JP2009528987A5 (member.php) | 2010-04-02 |
| JP5198290B2 true JP5198290B2 (ja) | 2013-05-15 |
Family
ID=38345897
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008553534A Expired - Fee Related JP5198290B2 (ja) | 2006-02-02 | 2007-02-02 | 免疫反応を誘発する酵母ベースワクチン |
| JP2012260860A Pending JP2013075899A (ja) | 2006-02-02 | 2012-11-29 | 治療用組成物 |
| JP2014230982A Withdrawn JP2015038147A (ja) | 2006-02-02 | 2014-11-13 | 免疫反応を誘発する酵母ベースワクチン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012260860A Pending JP2013075899A (ja) | 2006-02-02 | 2012-11-29 | 治療用組成物 |
| JP2014230982A Withdrawn JP2015038147A (ja) | 2006-02-02 | 2014-11-13 | 免疫反応を誘発する酵母ベースワクチン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7736642B2 (member.php) |
| EP (2) | EP1988919A4 (member.php) |
| JP (3) | JP5198290B2 (member.php) |
| KR (2) | KR20140029551A (member.php) |
| CN (2) | CN101405026B (member.php) |
| AU (1) | AU2007212076B2 (member.php) |
| BR (1) | BRPI0706913A2 (member.php) |
| CA (1) | CA2638815A1 (member.php) |
| IL (2) | IL193196A (member.php) |
| IN (1) | IN2014DN08830A (member.php) |
| MX (1) | MX2008009929A (member.php) |
| SG (2) | SG169375A1 (member.php) |
| TW (2) | TW200806316A (member.php) |
| WO (1) | WO2007092792A2 (member.php) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002039951A2 (en) * | 2000-11-15 | 2002-05-23 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| US8343502B2 (en) * | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| BR0316758A (pt) * | 2002-12-16 | 2005-10-25 | Globeimmune Inc | Vacinas baseadas em levedura como imunoterapia |
| BRPI0613025A2 (pt) * | 2005-07-11 | 2010-12-14 | Globeimmune Inc | composiÇço para reduzir a resistÊncia a um agente, mÉtodo para a preparaÇço de um veÍculo de levedura e uso da composiÇço |
| US20070172503A1 (en) * | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| SG169375A1 (en) * | 2006-02-02 | 2011-03-30 | Globeimmune Inc | Yeast-based vaccine for inducing an immune response |
| GB0613977D0 (en) | 2006-02-07 | 2006-08-23 | Peptcell Ltd | Peptide sequences and compositions |
| US9101578B2 (en) * | 2006-05-01 | 2015-08-11 | Technovax, Inc. | Polyvalent influenza virus-like particle (VLP) compositions |
| EP1998814A4 (en) * | 2006-05-11 | 2010-06-16 | Novavax Inc | NEW VACCINES AGAINST INFLUENZA M2 |
| US9511134B2 (en) * | 2006-05-18 | 2016-12-06 | Epimmune Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| PL2121013T3 (pl) * | 2007-02-02 | 2015-05-29 | Globeimmune Inc | Sposoby wytwarzania szczepionek na bazie drożdży |
| RU2505313C2 (ru) * | 2007-03-19 | 2014-01-27 | Глоубиммьюн, Инк. | Композиции и способы направленного устранения мутационного ускользания в направленной терапии рака |
| GB0719526D0 (en) * | 2007-10-05 | 2007-11-14 | Isis Innovation | Compositions and methods |
| US20100285050A1 (en) | 2007-10-05 | 2010-11-11 | Isis Innovation Limited | Compositions and Methods |
| WO2010036948A2 (en) * | 2008-09-26 | 2010-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Dna prime/inactivated vaccine boost immunization to influenza virus |
| JP5759980B2 (ja) | 2009-04-17 | 2015-08-05 | グローブイミューン，インコーポレイテッド | 癌および感染症に対する免疫療法組成物の組み合わせ |
| EP2432503A4 (en) * | 2009-05-18 | 2013-01-23 | Panacea Biotec Ltd | BASED ON RECOMBINANTLY MODIFIED VACCINIA ANKARA VIRUS UNIVERSAL GRIP VACCINATE |
| WO2011032119A1 (en) | 2009-09-14 | 2011-03-17 | The Regents Of The University Of Colorado | Modulation of yeast-based immunotherapy products and responses |
| US20120015346A1 (en) * | 2010-07-08 | 2012-01-19 | New York Medical College | Influenza virus detection and diagnosis |
| CA2813078A1 (en) * | 2010-10-04 | 2012-04-12 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
| US9173933B2 (en) * | 2010-10-15 | 2015-11-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara influenza vaccine |
| US9254320B2 (en) | 2010-12-17 | 2016-02-09 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| WO2012106231A2 (en) * | 2011-01-31 | 2012-08-09 | Baxter International Inc. | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses |
| PH12013501683A1 (en) | 2011-02-12 | 2019-07-17 | Globeimmune Inc | Yeast-based therapeutic for chronic hepatitis b infection |
| CN103648513B (zh) * | 2011-03-17 | 2018-10-12 | 全球免疫股份有限公司 | 酵母-Brachyury(短尾畸形)免疫治疗组合物 |
| CN103732249A (zh) * | 2011-05-23 | 2014-04-16 | 威斯特解剖及生物研究所 | 含有经修饰腺病毒载体的流感疫苗 |
| SG10201605265TA (en) | 2011-06-14 | 2016-08-30 | Globeimmune Inc | Yeast-Based Compositions and Methods for the Treatment or Prevention of Hepatitis Delta Virus Infection |
| JP6113155B2 (ja) * | 2011-06-20 | 2017-04-12 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原 |
| EP2744918A4 (en) | 2011-08-17 | 2015-06-10 | Globeimmune Inc | IMMUNOTHERAPEUTIC YEAST MUC1 COMPOSITIONS AND USES THEREOF |
| ES2525205T3 (es) * | 2011-11-09 | 2014-12-18 | Werner Lubitz | Vacuna para su uso en inmunoterapia tumoral |
| DE102011121069A1 (de) | 2011-12-13 | 2013-06-13 | Martin-Luther-Universität Halle-Wittenberg | Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene |
| US9653272B2 (en) | 2012-06-26 | 2017-05-16 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| US20140065173A1 (en) | 2012-09-06 | 2014-03-06 | Orbis Health Solutions Llc | Tumor lysate loaded particles |
| JP5954079B2 (ja) | 2012-09-25 | 2016-07-20 | ソニー株式会社 | 培養観察装置及び培養観察方法 |
| EP2929351B1 (en) * | 2012-12-10 | 2019-10-09 | The University of Queensland | Cell-free biofragment compositions and related systems, devices, and methods |
| CA2898237A1 (en) * | 2013-03-15 | 2014-09-25 | The Trustees Of The University Of Pennsylvania | Vaccines having an antigen and interleukin-23 as an adjuvant |
| SG11201507328RA (en) | 2013-03-19 | 2015-10-29 | Globeimmune Inc | Yeast-based immunotherapy for chordoma |
| EP2978449B1 (en) * | 2013-03-26 | 2021-09-08 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| JP2014210747A (ja) * | 2013-04-19 | 2014-11-13 | アンジェスＭｇ株式会社 | 細胞性免疫誘導能が改善された経口ワクチン |
| TWI654200B (zh) | 2013-08-30 | 2019-03-21 | 環球免疫公司 | 治療或預防結核病的組合物及方法 |
| US10835595B2 (en) | 2014-01-06 | 2020-11-17 | The Trustees Of The University Of Pennsylvania | PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy |
| JP6797022B2 (ja) | 2014-03-05 | 2020-12-09 | オービス ヘルス ソリューションズ エルエルシー | 酵母細胞壁粒子を用いたワクチン送達系 |
| EP3129036B1 (en) | 2014-04-11 | 2021-08-11 | Globeimmune, Inc. | Yeast-based immunotherapy and type i interferon sensitivity |
| CN105233302B (zh) * | 2014-07-10 | 2018-10-19 | 中国人民解放军军事医学科学院生物工程研究所 | 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法 |
| EP3256140B1 (en) | 2015-01-09 | 2020-04-01 | Etubics Corporation | Compositions for ebola virus vaccination |
| WO2016168187A1 (en) * | 2015-04-13 | 2016-10-20 | The Regents Of The University Of Michigan | Virus-like particles |
| EP3331552B1 (en) | 2015-08-03 | 2021-01-27 | Globeimmune, Inc. | Modified yeast-brachyury immunotherapeutic compositions |
| CN108367060B (zh) * | 2015-08-11 | 2022-07-19 | 奥比思健康解决方案有限责任公司 | 细菌和病毒疫苗策略 |
| GB2552441A (en) * | 2015-10-22 | 2018-01-31 | Royal Veterinary College | Methods |
| EP3195878A1 (en) | 2016-01-22 | 2017-07-26 | Werner Lubitz | Bacterial ghosts for the treatment of cancer |
| EP3475434A4 (en) | 2016-03-24 | 2020-07-29 | Nantcell, Inc. | SEQUENCES AND SEQUENCES ARRANGEMENTS FOR PRESENTATION OF NEO-EPITOPIA |
| IL270132B2 (en) | 2017-04-24 | 2024-12-01 | Nantcell Inc | Neoepitope vectors and methods for them |
| CN111556896A (zh) | 2017-12-21 | 2020-08-18 | 株式会社绿色生物医药 | 交叉免疫抗原疫苗及其制备方法 |
| DE102017012109A1 (de) * | 2017-12-27 | 2019-06-27 | Martin-Luther-Universität Halle-Wittenberg | Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis |
| WO2019222073A1 (en) | 2018-05-15 | 2019-11-21 | Globeimmune, Inc. | Lysates of recombinant yeast for inducing cellular immune responses |
| EP3851120A4 (en) * | 2018-09-11 | 2022-04-27 | Shanghai Public Health Clinical Center | Immunogen for broad-spectrum influenza vaccine and application thereof |
| WO2020061203A1 (en) | 2018-09-21 | 2020-03-26 | Nantcell, Inc. | Methods and compositions for modulating myeloid-derived suppressor cells |
| JP2022532922A (ja) * | 2019-05-21 | 2022-07-20 | エスペロバックス インコーポレイティド | 酵母ベースの経口ワクチン接種 |
| KR20220152226A (ko) * | 2020-02-11 | 2022-11-15 | 사이토누스 테라퓨틱스, 인크. | 신속한 백신 플랫폼 |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| WO2021211691A1 (en) | 2020-04-14 | 2021-10-21 | Immunitybio, Inc. | Yeast lysate covid-19 vaccine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
| US5830463A (en) * | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| JPH09511381A (ja) | 1994-01-11 | 1997-11-18 | ブラームス・インターユニバージテーア・インスティテュート・ボーア・ビーオテクノロジー | インフルエンザワクチン |
| US5691189A (en) * | 1994-01-19 | 1997-11-25 | Bristol-Myers Squibb Company | Saccharomyces cerevisiae expressing M2 protein of influenza A virus |
| US6696251B1 (en) * | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US20020044948A1 (en) * | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| DK1294892T3 (da) * | 2000-06-23 | 2008-01-28 | Wyeth Corp | Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er) |
| WO2002039951A2 (en) * | 2000-11-15 | 2002-05-23 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| US20030008000A1 (en) * | 2001-03-08 | 2003-01-09 | Wong Jonathan P. | DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus |
| US20030202982A1 (en) * | 2001-08-15 | 2003-10-30 | Birkett Ashley J. | Influenza immunogen and vaccine |
| BR0316758A (pt) * | 2002-12-16 | 2005-10-25 | Globeimmune Inc | Vacinas baseadas em levedura como imunoterapia |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| US8592197B2 (en) * | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| US20060024670A1 (en) * | 2004-05-18 | 2006-02-02 | Luke Catherine J | Influenza virus vaccine composition and methods of use |
| KR20070054246A (ko) * | 2004-09-17 | 2007-05-28 | 유니버시티 오브 매사추세츠 | 리소좀성 효소 결핍을 위한 조성물 및 이의 용도 |
| SG169375A1 (en) * | 2006-02-02 | 2011-03-30 | Globeimmune Inc | Yeast-based vaccine for inducing an immune response |
-
2007
- 2007-02-02 SG SG201100779-6A patent/SG169375A1/en unknown
- 2007-02-02 WO PCT/US2007/061572 patent/WO2007092792A2/en not_active Ceased
- 2007-02-02 EP EP07717549A patent/EP1988919A4/en not_active Withdrawn
- 2007-02-02 BR BRPI0706913-8A patent/BRPI0706913A2/pt not_active Application Discontinuation
- 2007-02-02 SG SG10201402236VA patent/SG10201402236VA/en unknown
- 2007-02-02 JP JP2008553534A patent/JP5198290B2/ja not_active Expired - Fee Related
- 2007-02-02 CN CN200780009861.4A patent/CN101405026B/zh not_active Expired - Fee Related
- 2007-02-02 KR KR1020147004408A patent/KR20140029551A/ko not_active Withdrawn
- 2007-02-02 CN CN201510122553.9A patent/CN104826102A/zh not_active Withdrawn
- 2007-02-02 MX MX2008009929A patent/MX2008009929A/es active IP Right Grant
- 2007-02-02 AU AU2007212076A patent/AU2007212076B2/en not_active Ceased
- 2007-02-02 TW TW096103976A patent/TW200806316A/zh unknown
- 2007-02-02 TW TW102144486A patent/TW201412329A/zh unknown
- 2007-02-02 CA CA002638815A patent/CA2638815A1/en not_active Withdrawn
- 2007-02-02 US US11/670,902 patent/US7736642B2/en not_active Expired - Fee Related
- 2007-02-02 KR KR20087020923A patent/KR101492524B1/ko not_active Ceased
- 2007-02-02 EP EP11180828.3A patent/EP2468296A3/en not_active Withdrawn
- 2007-02-02 IN IN8830DEN2014 patent/IN2014DN08830A/en unknown
-
2008
- 2008-07-31 IL IL193196A patent/IL193196A/en active IP Right Review Request
-
2010
- 2010-04-16 US US12/762,221 patent/US20100196411A1/en not_active Abandoned
-
2012
- 2012-11-29 JP JP2012260860A patent/JP2013075899A/ja active Pending
-
2014
- 2014-05-08 IL IL232518A patent/IL232518A0/en unknown
- 2014-11-13 JP JP2014230982A patent/JP2015038147A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201402236VA (en) | 2014-08-28 |
| EP2468296A2 (en) | 2012-06-27 |
| US20080003239A1 (en) | 2008-01-03 |
| EP1988919A2 (en) | 2008-11-12 |
| US7736642B2 (en) | 2010-06-15 |
| CN104826102A (zh) | 2015-08-12 |
| KR101492524B1 (ko) | 2015-02-12 |
| IL232518A0 (en) | 2014-06-30 |
| AU2007212076A1 (en) | 2007-08-16 |
| BRPI0706913A2 (pt) | 2011-04-12 |
| JP2009528987A (ja) | 2009-08-13 |
| WO2007092792A3 (en) | 2008-02-28 |
| SG169375A1 (en) | 2011-03-30 |
| IN2014DN08830A (member.php) | 2015-07-10 |
| JP2013075899A (ja) | 2013-04-25 |
| WO2007092792A2 (en) | 2007-08-16 |
| AU2007212076B2 (en) | 2012-10-18 |
| KR20140029551A (ko) | 2014-03-10 |
| TW200806316A (en) | 2008-02-01 |
| JP2015038147A (ja) | 2015-02-26 |
| CN101405026B (zh) | 2015-04-22 |
| IL193196A0 (en) | 2011-08-01 |
| TW201412329A (zh) | 2014-04-01 |
| EP2468296A3 (en) | 2013-12-04 |
| US20100196411A1 (en) | 2010-08-05 |
| IL193196A (en) | 2015-01-29 |
| KR20080089671A (ko) | 2008-10-07 |
| CA2638815A1 (en) | 2007-08-16 |
| CN101405026A (zh) | 2009-04-08 |
| MX2008009929A (es) | 2008-10-01 |
| EP1988919A4 (en) | 2009-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5198290B2 (ja) | 免疫反応を誘発する酵母ベースワクチン | |
| CN101437964B (zh) | 基于酵母的对慢性丙型肝炎感染的治疗 | |
| US10849971B2 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
| JP2014523878A (ja) | Ｄ型肝炎ウイルス感染の治療又は予防のための酵母ベースの組成物及び方法 | |
| JP2012503011A (ja) | 慢性ｃ型肝炎ウイルス感染の免疫療法 | |
| CA3170359A1 (en) | Yeast lysate covid-19 vaccine | |
| AU2013200249A1 (en) | Yeast-based vaccine for inducing an immune response | |
| HK1172556A (en) | Yeast-based vaccine for inducing an immune response | |
| US20250009825A1 (en) | Lysates of recombinant yeast for inducing cellular immune responses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100201 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100201 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20110114 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110225 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20110613 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110628 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120529 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120822 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120829 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121129 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130108 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130206 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160215 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |